• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Immunol . ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19

tetano

Editor, Senior Moderator
Nat Immunol


. 2023 Jun 15.
doi: 10.1038/s41590-023-01513-1. Online ahead of print. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19

Paulina Kaplonek[SUP] #[/SUP][SUP] 1 [/SUP], Deniz Cizmeci[SUP] #[/SUP][SUP] 1 [/SUP], Gaurav Kwatra[SUP] #[/SUP][SUP] 2 3 4 [/SUP], Alane Izu[SUP] 2 3 4 [/SUP], Jessica Shih-Lu Lee[SUP] 1 [/SUP], Harry L Bertera[SUP] 1 [/SUP], Stephanie Fischinger[SUP] 1 [/SUP], Colin Mann[SUP] 5 [/SUP], Fatima Amanat[SUP] 6 [/SUP], Wenjun Wang[SUP] 7 [/SUP], Anthonet L Koen[SUP] 2 3 [/SUP], Lee Fairlie[SUP] 4 8 [/SUP], Clare L Cutland[SUP] 4 [/SUP], Khatija Ahmed[SUP] 9 [/SUP], Keertan Dheda[SUP] 10 11 [/SUP], Shaun L Barnabas[SUP] 12 [/SUP], Qasim Ebrahim Bhorat[SUP] 13 [/SUP], Carmen Briner[SUP] 14 [/SUP], Florian Krammer[SUP] 6 [/SUP], Erica Ollman Saphire[SUP] 5 [/SUP], Sarah C Gilbert[SUP] 15 [/SUP], Teresa Lambe[SUP] 16 [/SUP], Andrew J Pollard[SUP] 16 [/SUP], Marta Nunes[SUP] 2 3 4 [/SUP], Manfred Wuhrer[SUP] 7 [/SUP], Douglas A Lauffenburger[SUP] 17 [/SUP], Shabir A Madhi[SUP] #[/SUP][SUP] 18 19 20 [/SUP], Galit Alter[SUP] #[/SUP][SUP] 21 [/SUP]



Affiliations
Abstract

Despite the success of COVID-19 vaccines, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern have emerged that can cause breakthrough infections. Although protection against severe disease has been largely preserved, the immunological mediators of protection in humans remain undefined. We performed a substudy on the ChAdOx1 nCoV-19 (AZD1222) vaccinees enrolled in a South African clinical trial. At peak immunogenicity, before infection, no differences were observed in immunoglobulin (Ig)G1-binding antibody titers; however, the vaccine induced different Fc-receptor-binding antibodies across groups. Vaccinees who resisted COVID-19 exclusively mounted FcγR3B-binding antibodies. In contrast, enhanced IgA and IgG3, linked to enriched FcγR2B binding, was observed in individuals who experienced breakthrough. Antibodies unable to bind to FcγR3B led to immune complex clearance and resulted in inflammatory cascades. Differential antibody binding to FcγR3B was linked to Fc-glycosylation differences in SARS-CoV-2-specific antibodies. These data potentially point to specific FcγR3B-mediated antibody functional profiles as critical markers of immunity against COVID-19.


 
Back
Top Bottom